Researchers analyzed data from 108,647 postmenopausal women diagnosed with breast cancer to see if there was an increased risk of the disease for those who used menopausal hormone therapy.
In 2017, about half of physician directors at National Cancer Institute cancer centers received payments related to research, while a quarter received payments over $5,000 that were not related to research.
The international retrospective study included 365 patients with newly diagnosed early-stage follicular lymphoma rigorously staged with PET-CT and bone marrow biopsy.
Switching from intravenous to subcutaneous administration of rituximab for non-Hodgkin diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL) resulted in similar efficacy with no new safety issues.
A survey of physicians found recruiting for trials through social media can be useful, but not for cancer therapeutic trials.
Autologous stem cell transplant has become safer over the years for patients with multiple myeloma and renal insufficiency.
CAR T cells are a more effective therapy if manufactured for patients with multiple myeloma prior to the onset of relapsed or refractory disease.
A combination of pegilodecakin (pegylated IL-10) with an anti-PD-L1 monoclonal antibody inhibitor showed preliminary antitumor activity.
After the FDA restricted the labels of 2 drugs used to treat bladder cancer, oncologists' use of these treatments decreased drastically.
Adding the immunotherapy pembrolizumab to neoadjuvant chemotherapy improved the pathological complete response rate in patients with early triple-negative breast cancer, according to findings of a study presented at ESMO.